Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:03 PM ET 10-Q
Financial Results Align Technology Inc ALGN

Align Technology Q3 2026 Results: Net Income $135M, Up 138.0% YoY

Align Technology reported net revenues of $1.01 billion for the third quarter of 2026, a slight increase from $995.7 million in the prior year. Net income for the quarter rose significantly to $135.0 million compared to $56.8 million in Q3 2025, driven by lower costs of revenues and reduced restructuring charges.

Key figure
Net income $135M · +138.0% YoY
4:03 PM ET 8-K
Financial Results TWFG, Inc. TWFG

TWFG Financial Results

TWFG, Inc. reported third quarter 2026 financial results with total revenues increasing 24.6% year-over-year to $79.9 million. The growth was driven by a 25.9% increase in commission income and an 18.5% rise in total written premium, reflecting strong organic and inorganic performance across its agency and MGA platforms.

Term
Q3 2026

“Our third quarter results highlight the strength of TWFG’s diversified platform. Written premium grew 18.5%, total revenues increased 24.6%, and Adjusted EBITDA rose 15.0%, supported by growth across Agency-in-a-Box, Corporate Stores and MGA programs, as well as contributions from recent acquisitions. We continued to grow in a moderating rate environment, demonstrating the value we bring to agents, policyholders and carrier partners.”

Gordy Bunch, CEO
4:03 PM ET 10-Q
Financial Results Sprout Social, Inc. SPT

Sprout Social Q3 2026 Results: Net Loss of $6.45M, Loss Narrows

Sprout Social reported a decrease in total assets from $523.1 million at the end of 2025 to $493.2 million as of September 30, 2026, primarily driven by a reduction in accounts receivable. The company also reduced its total liabilities from $319.6 million to $286.1 million, including a $7.5 million paydown on its revolving credit facility.

Key figure
Net loss $6.45M
4:03 PM ET 8-K
Financial Results HMH Holding Inc HMH

HMH Holding Financial Results

HMH Holding Inc. reported third quarter 2026 revenue of $171.1 million and net income of $5.0 million. While revenue declined 21% year-over-year due to lower volume across product lines, the company achieved a book-to-bill ratio of 1.12x and expanded its aftermarket platform through the acquisition of Deepwater Riser Services.

Term
Q3 2026

“Equipment order activity remained below our expectations in the third quarter as several larger equipment and upgrade opportunities shifted to later periods. Customer contract awards took longer than anticipated, narrowing execution windows for certain projects, while customers remained disciplined in their capital deployment. Importantly, we have not seen these opportunities disappear and continue to see a healthy pipeline across our installed base. Stronger service activity, favorable business mix, and disciplined cost execution provide resilience as we navigate this near-term variability and position the business for the next phase of market activity.”

Eirik Bergsvik, Chief Executive Officer

“Looking ahead, we are taking deliberate actions to strengthen HMH’s competitive and financial position as these opportunities convert. We are maintaining critical equipment capabilities, investing in long-lead materials to improve delivery readiness and cost positioning, and expanding our aftermarket platform through the acquisition of Deepwater Riser Services. As part of this strategy, we are consolidating our U.S. Gulf riser operations in Houma, Louisiana, creating a more focused and efficient operating footprint while expanding our riser inspection, recertification, refurbishment, and storage capabilities.”

Eirik Bergsvik, Chief Executive Officer
4:03 PM ET 10-Q
Financial Results Solid Biosciences Inc. SLDB

Solid Biosciences Q3 2026 Results: Net Loss of $53.9M, Loss Widens

Solid Biosciences Inc. reported a significant increase in cash, cash equivalents, and available-for-sale securities, totaling approximately $348.9 million as of September 30, 2026, compared to $187.9 million at year-end 2025. The company's accumulated deficit grew to $1.12 billion, reflecting ongoing losses as it advances its neuromuscular and cardiac clinical candidates.

Key figure
Net loss $53.9M
4:03 PM ET 10-Q
Financial Results Arko Petroleum Corp. APC

Arko Petroleum Q3 2026 Results: Net Income $13.3M, Up 32.1% YoY

ARKO Petroleum Corp. reported significant growth in fuel revenue for the nine months ended September 30, 2026, reaching $3.05 billion compared to $2.43 billion in the prior year. The company underwent a capital structure change during the period, transitioning from a net investment by ARKO Parent to a multi-class common stock structure with 12,570,223 Class A and 35,000,000 Class B shares outstanding.

Key figure
Net income $13.3M · +32.1% YoY
4:03 PM ET 8-K
Financial Results Maravai Lifesciences Holdings, Inc. MRVI

Maravai Lifesciences Holdings Financial Results

Maravai LifeSciences reported Q3 2026 total revenue of $45.9 million, a 10% increase year-over-year, driven by strong demand for mRNA products and GMP consumables. The company narrowed its net loss to $24.0 million and raised its full-year 2026 revenue and Adjusted EBITDA guidance based on positive momentum in its TriLink and Cygnus segments.

Term
Q3 2026

“Our third- quarter results build on the momentum we established in the first half of the year. TriLink revenue grew 12% year-over-year led by 28% revenue growth for our mRNA products, while Cygnus delivered its sixth consecutive quarter of year-over-year growth, with revenue up 8%.”

Bernd Brust, CEO of Maravai LifeSciences

“Four Discovery mRNA customers transitioned to clinical-stage GMP this quarter, reinforcing our belief that today’s Discovery success will create tomorrow’s GMP opportunity. Based on our third-quarter performance and our expectations for the fourth quarter, we are raising our full-year revenue and adjusted EBITDA guidance.”

Bernd Brust, CEO of Maravai LifeSciences
4:03 PM ET 8-K
Financial Results Power Integrations Inc POWI

Power Integrations Financial Results

Power Integrations reported Q3 2026 revenue of $125.5 million, a 5% sequential increase driven by PowiGaN products and industrial market strength. The company also announced an increase in its quarterly dividend to $0.22 per share starting in 2027 and provided Q4 revenue guidance of $118 million to $126 million.

Term
Q3 2026

“Revenue grew five percent over the prior quarter driven by PowiGaN™ products as well as continued strength in the industrial market, where revenue is up 13 percent year-to-date. We also delivered strong earnings growth in the quarter reflecting our continued focus on expense discipline and profitability. Power is becoming a critical constraint thanks to AI and electrification, calling for dramatic advances in efficiency and power density. Our high-voltage technology and system expertise are well aligned with these challenges, and we are excited about our product roadmap and the opportunities ahead to drive shareholder value.”

Jen Lloyd, CEO
4:03 PM ET 8-K
Financial Results Hamilton Beach Brands Holding Co HBB

Hamilton Beach Brands Holding Financial Results

Hamilton Beach Brands reported Q3 2026 revenue growth of 5.6% to $140.3 million, driven by a recovery in its U.S. consumer business and strong growth in its Health segment. Operating profit rose 52.6% to $4.4 million as gross margins improved significantly following the mitigation of tariff-related headwinds from the prior year. However, the company lowered its full-year outlook due to cautious holiday inventory commitments from retail partners amid declining consumer sentiment.

Term
Q3 2026

“Our third quarter results were in line with our expectations and reflect the recovery of our U.S. consumer business following last year’s tariff related headwinds, coupled with the margin benefits from our ongoing tariff mitigation actions.”

R. Scott Tidey, President and Chief Executive Officer

“Unfortunately, with consumer sentiment declining over the past couple of months, several of our retail partners have become more cautious with their inventory commitments for the upcoming holiday season. As a result, we now expect fourth-quarter sales to be lower than previously anticipated and have revised our full-year outlook accordingly.”

R. Scott Tidey, President and Chief Executive Officer
4:03 PM ET 8-K
Financial Results Arcutis Biotherapeutics, Inc. ARQT

Arcutis Biotherapeutics Financial Results

Arcutis Biotherapeutics reported Q3 2026 net product revenues of $143.9 million, a 45% year-over-year increase driven by strong demand for its ZORYVE portfolio. The company maintained positive operating cash flow of $18.9 million and raised its full-year 2026 net product sales guidance to a range of $535 million to $545 million.

Term
quarter ended September 30, 2026

“Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations.”

Frank Watanabe, president and chief executive officer
4:03 PM ET 10-Q
Financial Results Viper Energy, Inc. VNOM

Viper Energy Q3 2026 Results: Turns Profitable, Net Income $140M

Viper Energy, Inc. filed its Q3 2026 report showing 192,668,368 Class A and 168,551,337 Class B shares outstanding as of October 30, 2026. The company continues to focus on mineral and royalty interests in the Permian Basin, highlighting recent strategic transactions including the Riverbend and McElroy Ranch acquisitions.

Key figure
Net income $140M
4:03 PM ET 10-Q
Financial Results Sixth Street Lending Partners

Sixth Street Lending Partners Q3 2026 Results: Net Income $117M, Down 15.7% YoY

For the nine months ended September 30, 2026, Sixth Street Lending Partners reported total investment income of $703.1 million and net investment income of $433.2 million. The company's net asset value per share decreased to $28.13 from $28.51 at the end of 2025, primarily driven by $162.6 million in total net unrealized and realized losses.

Key figure
Net income $117M · -15.7% YoY
4:03 PM ET 10-Q
Financial Results CDW Corp CDW ▶ Call

CDW Q3 2026 Results: Net Income $310M, Up 6.5% YoY

CDW Corp reported net sales of $6.75 billion for the third quarter of 2026, a significant increase from $5.74 billion in the prior year period. Net income rose to $309.8 million, supported by strong operating income growth, while the company continued its capital return strategy through $652.7 million in share repurchases during the first nine months of the year.

Key figure
Net income $310M · +6.5% YoY
4:03 PM ET 10-Q
Financial Results Foster L B Co FSTR

Foster L B Q3 2026 Results: Net Income $6.77M, Up 56.5% YoY

L.B. Foster Company reported a significant increase in net income for the nine months ended September 30, 2026, reaching $11.4 million compared to $5.0 million in the prior year period. Total net sales grew by 12.7% year-over-year to $427.7 million, driven by strong performance in both goods and services segments.

Key figure
Net income $6.77M · +56.5% YoY
4:02 PM ET 10-Q
Financial Results Blue Owl Capital Corp OBDC ▶ Call

Blue Owl Capital Q3 2026 Results: Net Income $180M, Up 40.5% YoY

Blue Owl Credit SLF LLC reported a net increase in members' equity from operations of $31.0 million for the quarter ended September 30, 2026, up from $13.3 million in the prior year period. Total assets grew significantly to $3.56 billion compared to $2.48 billion at year-end 2025, driven by an increase in investments at fair value.

Key figure
Net income $180M · +40.5% YoY
4:02 PM ET 10-Q
Financial Results Blue Owl Technology Finance Corp. OTF ▶ Call

Blue Owl Technology Finance Q3 2026 Results: Net Income $219M, Down 6.7% YoY

Blue Owl Credit SLF LLC reported total investment income of $49.7 million for the quarter ended September 30, 2026, and a net increase in members' equity from operations of $31.0 million. Total assets grew significantly to $3.56 billion from $2.48 billion at the end of 2025, driven by an increase in investments at fair value.

Key figure
Net income $219M · -6.7% YoY
4:02 PM ET 8-K
Financial Results Xencor Inc XNCR

Xencor Financial Results

Xencor reported financial results for the third quarter ended September 30, 2026, highlighting clinical progress for its lead bispecific antibody XmAb819 in renal cell carcinoma. The company ended the quarter with $412.4 million in cash and equivalents, providing a projected runway into 2028.

“Xencor’s lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcinoma, and our plans for moving XmAb819 into earlier lines of treatment as a monotherapy and in combination with anti-PD(L)1 are underway, with evaluation of XmAb819 in additional ENPP3-positive tumor types also ongoing.”

Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor
4:02 PM ET 8-K
Financial Results Cirrus Logic, Inc. CRUS

Cirrus Logic Financial Results

Cirrus Logic reported Q2 FY2027 revenue of $559.5 million and GAAP EPS of $2.23, driven by strong demand for smartphone components. The company also announced that its Board of Directors authorized an additional $500 million for its stock repurchase program.

“Cirrus Logic delivered solid results in the September quarter primarily driven by strong demand and increased content shipping into smartphones. During the quarter we were pleased to see our custom components featured in newly launched smartphones, in addition to broader adoption of our third-generation camera controller in these devices.”

John Forsyth, Cirrus Logic president and chief executive officer

“We also made progress on new product development as we began sampling our analog front-end components for smart metering and taped out both our fourth-generation camera controller for smartphones and second-generation smart codec for AI-enabled PCs. With an extensive roadmap and strong pipeline of opportunities, we remain confident in our ability to grow long-term shareholder value.”

John Forsyth, Cirrus Logic president and chief executive officer
4:02 PM ET 10-Q
Financial Results Edgewise Therapeutics, Inc. EWTX

Edgewise Therapeutics Q3 2026 Results: Turns Profitable, Net Income $1.17B

Edgewise Therapeutics reported 109,482,763 shares of common stock outstanding as of October 31, 2026. The company is focusing its resources on the development of EDG-7500 and EDG-15400 following the Sevasemten Sale, which has impacted its operating expenses and cash position.

Key figure
Net income $1.17B
4:02 PM ET 10-Q
Financial Results Purple Innovation, Inc. PRPL ▶ Call

Purple Innovation Q3 2026 Results: Net Loss of $1.4M, Loss Narrows

Purple Innovation reported a net loss of $35.2 million for the nine months ended September 30, 2026, an improvement from a $48.3 million loss in the prior year period. Revenues decreased 11.4% year-over-year to $290.5 million, while the company significantly reduced its operating loss through lower marketing and sales expenses and reduced restructuring charges.

Key figure
Net loss $1.4M
4:02 PM ET 8-K
Financial Results Edgewise Therapeutics, Inc. EWTX

Edgewise Therapeutics Financial Results

Edgewise Therapeutics reported Q3 2026 financial results, highlighting a $1.348 billion gain from the sale of sevasemten to Servier. The company ended the quarter with $1.74B in cash and is on track to initiate a Phase 3 trial for EDG-7500 in HCM by year-end 2026.

“Our third quarter reflects continued execution across both cardiovascular programs. In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026.”

Kevin Koch, Ph.D., President and Chief Executive Officer
4:02 PM ET 10-Q
Financial Results Niagen Bioscience, Inc. NAGE ▶ Call

Niagen Bioscience Q3 2026 Results: Net Loss of $1.17M

Niagen Bioscience reported a net loss of $1.2 million for the third quarter of 2026, a significant decline from a $4.6 million profit in the prior year, driven by a 20% decrease in net sales. However, for the nine-month period, the company remained profitable with a net income of $6.1 million, bolstered by a $4.8 million gain from the sale of an operating segment.

Key figure
Net loss $1.17M
4:02 PM ET 8-K
Financial Results Arko Petroleum Corp. APC

Arko Petroleum Financial Results

ARKO Petroleum Corp. reported third quarter 2026 net income of $13.3 million and Adjusted EBITDA of $41.0 million, representing year-over-year growth. The company raised its full-year 2026 Adjusted EBITDA guidance and declared a quarterly dividend of $0.50 per share.

Term
Q3 2026

“APC’s third-quarter results reinforce the strategy we outlined at the IPO. Adjusted EBITDA and Discretionary Cash Flow grew year over year, which we believe demonstrated the durability of our platform, the stability of its cash generation and our team’s ability to execute effectively through a volatile market environment. Based on year-to-date performance, our outlook for the balance of the year and the expected closing of USPP, we are raising our full-year 2026 Adjusted EBITDA guidance.”

Arie Kotler, Chairman, President and Chief Executive Officer of APC
4:02 PM ET 8-K
Financial Results Mercadolibre Inc MELI

Mercadolibre Financial Results

MercadoLibre reported third-quarter 2026 net revenues of $10.75 billion, a 45% increase year-over-year, driven by strong performance in Brazil and deepening ecosystem engagement. Net income for the period was $448 million, while income from operations decreased 6% to $676 million due to investments in free shipping, fulfillment capacity, and marketing.

Term
Q3 2026
4:02 PM ET 10-Q
Financial Results AGL Private Credit Income Fund

AGL Private Credit Income Fund Q3 2026 Results: Turns Profitable, Net Income $19M

AGL Private Credit Income Fund reported total assets of $1.54 billion as of September 30, 2026, with a portfolio primarily consisting of non-controlled, non-affiliated investments valued at $1.46 billion. The fund maintained 27,060,888 common shares outstanding and reported total debt of $861.6 million, net of deferred financing costs.

Key figure
Net income $19M
4:02 PM ET 8-K
Financial Results Allegiant Travel CO ALGT

Allegiant Travel Financial Results

Allegiant Travel Company reported third quarter 2026 financial results, including a GAAP net loss of $15.2 million and an adjusted diluted loss per share of $0.03. The results reflect the first full quarter of operations following the acquisition of Sun Country, with total operating revenue increasing 71.1% year-over-year to $961.6 million.

Term
Q3 2026

“Allegiant delivered another quarter of operating profitability, expanding our adjusted operating margin by 340 basis points year over year on a pro forma basis in our seasonally slowest quarter, despite a more than 55 percent surge in fuel costs per gallon.”

Greg Anderson, chief executive officer of Allegiant Travel Company

“With strong booking momentum, we remain confident in our 2026 full-year adjusted earnings per share guidance of greater than $6.00, despite elevated fuel costs.”

Greg Anderson, chief executive officer of Allegiant Travel Company
4:02 PM ET 8-K
Financial Results Niagen Bioscience, Inc. NAGE

Niagen Bioscience Financial Results

Niagen Bioscience reported Q3 2026 net sales of $27.2 million and a net loss of $1.2 million, while generating $2.6 million in operating cash flow. The company launched several new products including Niagen NanoCloud topical and an at-home injection kit, while expanding retail distribution through Walmart.com, GNC, and Sam's Club.

Term
Q3 2026

“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform. We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”

Rob Fried, Chief Executive Officer
4:01 PM ET 10-Q
Financial Results Terreno Realty Corp TRNO

Terreno Realty Q3 2026 Results: Net Income $68.1M, Down 34.1% YoY

Terreno Realty Corp reported net income of $195.1 million for the nine months ended September 30, 2026, a decrease from $244.8 million in the prior year period primarily due to lower gains on real estate sales. Total revenues increased to $381.4 million from $338.9 million, while the company continued to expand its portfolio with $326.9 million in property acquisitions during the period.

Key figure
Net income $68.1M · -34.1% YoY
4:01 PM ET 8-K
Financial Results Arko Corp. ARKO

Arko Financial Results

ARKO Corp. subsidiary ARKO Petroleum Corp. reported third quarter 2026 net income of $13.3 million and Adjusted EBITDA of $41.0 million. Based on year-to-date performance and the pending acquisition of U.S. Petroleum Partners, LLC, the company raised its full-year 2026 Adjusted EBITDA guidance and declared a $0.50 per share quarterly dividend.

“APC’s third-quarter results reinforce the strategy we outlined at the IPO. Adjusted EBITDA and Discretionary Cash Flow grew year over year, which we believe demonstrated the durability of our platform, the stability of its cash generation and our team’s ability to execute effectively through a volatile market environment. Based on year-to-date performance, our outlook for the balance of the year and the expected closing of USPP, we are raising our full-year 2026 Adjusted EBITDA guidance.”

Arie Kotler, Chairman, President and Chief Executive Officer of APC
4:01 PM ET 10-Q
Financial Results Damora Therapeutics, Inc. DMRA

Damora Therapeutics Q3 2026 Results: Net Loss of $32M, Loss Widens

Damora Therapeutics reported a significant increase in operating expenses for the nine months ended September 30, 2026, totaling $102.7 million compared to $9.2 million in the prior year, primarily driven by R&D for candidates DMR-001, DMR-002, and DMR-003. The company ended the period with $528.5 million in cash and marketable securities following a substantial increase in ordinary shares outstanding to 61.9 million.

Key figure
Net loss $32M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.